Literature DB >> 21721130

The inverse type II β-turn on D-Trp-Phe, a pharmacophoric motif for MOR agonists.

Luca Gentilucci1, Alessandra Tolomelli, Rossella De Marco, Santi Spampinato, Andrea Bedini, Roberto Artali.   

Abstract

Herein we propose the D-Trp-Phe sequence within an inverse type II β-turn as a new kind of pharmacophoric motif for μ-opioid receptor (MOR) cyclopeptide agonists. Initially, we observed that c[Tyr-D-Pro-D-Trp-Phe-Gly] (4), an analogue of endomorphin-1 (H-Tyr-Pro-Trp-Phe-NH₂) lacking the crucial protonatable amino group of Tyr 1, is a MOR agonist with 10⁻⁸ M affinity. Molecular docking analysis suggested that the relevant interactions with the receptor involve D-Trp-Phe. The bioactive conformation of this region was investigated by selected derivatives of 4 designed to adopt an inverse type II β-turn. These efforts led to c[Tyr-Gly-D-Trp-Phe-Gly] (14) and to the cyclotetrapeptide c[D-Asp-1-amide-β-Ala-D-Trp-Phe] (15), showing improved nanomolar affinity. Both 14 and 15 selectively bind MOR, as they have negligible affinity for the κ- and δ-opioid receptors. Both 14 and 15 behave as partial MOR agonists in functional assays. Conformational and docking analyses confirm the role of the inverse β-turn in binding. These results indicate that the D-Trp-Phe inverse β-turn structure can be used for designing non-endomorphin-like peptidomimetic opioid agonists in general, characterized by an atypical mechanism of interaction between ligand and receptor.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21721130     DOI: 10.1002/cmdc.201100169

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  6 in total

1.  Synthesis, pharmacological evaluation and conformational investigation of endomorphin-2 hybrid analogues.

Authors:  Giordano Lesma; Severo Salvadori; Francesco Airaghi; Engin Bojnik; Anna Borsodi; Teresa Recca; Alessandro Sacchetti; Gianfranco Balboni; Alessandra Silvani
Journal:  Mol Divers       Date:  2012-11-04       Impact factor: 2.943

2.  Structural and biological exploration of phe(3)-phe(4)-modified endomorphin-2 peptidomimetics.

Authors:  Giordano Lesma; Severo Salvadori; Francesco Airaghi; Thomas F Murray; Teresa Recca; Alessandro Sacchetti; Gianfranco Balboni; Alessandra Silvani
Journal:  ACS Med Chem Lett       Date:  2013-07-11       Impact factor: 4.345

3.  The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior.

Authors:  Jane V Aldrich; Sanjeewa N Senadheera; Nicolette C Ross; Michelle L Ganno; Shainnel O Eans; Jay P McLaughlin
Journal:  J Nat Prod       Date:  2013-01-17       Impact factor: 4.050

4.  A Cyclic Tetrapeptide ("Cyclodal") and Its Mirror-Image Isomer Are Both High-Affinity μ Opioid Receptor Antagonists.

Authors:  Grazyna Weltrowska; Thi M-D Nguyen; Nga N Chung; JodiAnne Wood; Xiaoyu Ma; Jason Guo; Brian C Wilkes; Yang Ge; André Laferrière; Terence J Coderre; Peter W Schiller
Journal:  J Med Chem       Date:  2016-10-03       Impact factor: 7.446

5.  Pharmacological Characterization of µ-Opioid Receptor Agonists with Biased G Protein or β-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation.

Authors:  Justyna Piekielna-Ciesielska; Roberto Artali; Ammar A H Azzam; David G Lambert; Alicja Kluczyk; Luca Gentilucci; Anna Janecka
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

6.  Toward a Universal μ-Agonist Template for Template-Based Alignment Modeling of Opioid Ligands.

Authors:  Zhijun Wu; Victor J Hruby
Journal:  ACS Omega       Date:  2019-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.